Mar 27, 2017 7:35am EDT Matinas BioPharma Reports Positive Topline Data from Phase 1 Study of MAT2501
Mar 08, 2017 8:01am EST Matinas BioPharma Announces Positive Preclinical Efficacy Results of MAT2501 in an In Vitro Model of Mycobacterium abscessus Infection
Mar 06, 2017 8:05am EST Matinas BioPharma and NIH/NIAID Initiate Open-Label Extension to Phase 2a Study of MAT2203 in Chronic Mucocutaneous Candidiasis
Jan 26, 2017 7:00am EST Matinas BioPharma Provides Business Outlook and Sets Corporate Milestones for 2017
Jan 23, 2017 7:05am EST Matinas BioPharma to Present at Noble Capital Markets’ Thirteenth Annual Investor Conference
Jan 19, 2017 7:05am EST Matinas BioPharma Successfully Completes Warrant Tender Offer – Raises $13.5 Million from Exercise of Warrants
Dec 08, 2016 7:05am EST Matinas BioPharma Receives Contract Award from Cystic Fibrosis Foundation Therapeutics to Study MAT2501 for the Treatment of NTM-Infection in Pre-Clinical Models of CF
